All In Biotech

Drug Trial Radar · NCT03252626

Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke

Last checked: Nov 19, 2026Latest source record: Apr 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 950 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

950

Planned (sponsor's estimate)

Start

Apr 18, 2024

Primary completion

Dec 31, 2024

Study completion Jun 30, 2025

Sponsor

Lead sponsor
The First Hospital of Jilin UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 17, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ischemic stroke has a variety of treatments and currently drug therapy is one of the main treatments.A number of clinical studies have proved that alprostadil (PGE1) has pharmacological effects of significant dilation of blood vessels, inhibition of plate aggregation, anti-atherosclerosis and increased cerebral blood flow.Evaluate the 90-days efficacy by comparing two groups of patients'(one with alprostadil,another with placebo) mRS.

Conditions

  • Stroke

Interventions

  • AlprostadilDrug

    Alprostadil injection USP for intravascular infusion contains 500 micrograms Alprostadil, more commonly known as prostaglandin E1. Vasodilation, inhibition of platelet aggregation are among the most notable of these effects. 2ml Alprostadil injection added into 10ml 0.9% saline.

  • Normal salineDrug

    2ml normal saline injection added into 10ml 0.9% saline.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Modified Rankin Scale at Day 90Time frame: day 90

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.